$86.380
-0.605 (-0.70%)At close
HSIC News
HSIC Events
Henry Schein Appoints Emmanuel Caprais as CFO
Henry Schein (HSIC) announced that Emmanuel Caprais, former Senior Vice President and Chief Financial Officer of ITT, (ITT), has been named the Company's Senior Vice President and Chief Financial Officer effective November 4, 2026. Caprais will join the Henry Schein Leadership Team and report to Frederick Lowery, Chief Executive Officer of Henry Schein. After 18 years with the Company, Ronald South, Senior Vice President, Chief Financial Officer, will transition into a senior advisory role, effective November 4, 2026.
Applied BioCode Signs Distribution Agreement with Henry Schein
Applied BioCode announced a distribution agreement with Henry Schein to expand the availability of its BioCode MDx-3000 System and comprehensive molecular diagnostics menu. The BioCode MDx-3000 is an automated, high-throughput multiplex molecular diagnostic platform designed to support high-complexity clinical laboratories. Its testing menu includes upper respiratory and gastrointestinal infection panels, with a customizable menu option, enabling laboratories to deliver accurate, cost-effective, and efficient molecular diagnostic testing. Through this agreement, Henry Schein will distribute the MDx-3000 System and its associated assays to hospitals, health systems, and reference laboratories nationwide, helping broaden access to advanced molecular diagnostic capabilities.
Company Reports Q2 Revenue of $3.5B, Beating Expectations
Reports Q2 revenue $3.5B, consensus $3.37B. "We delivered strong sales performance and margin improvement in the second quarter, driven by sustained momentum across our businesses and solid operational execution by the team. Internal local currency sales growth accelerated compared to the first quarter, which, combined with strong gross margins and the early benefits from our value creation initiatives, drove strong earnings growth," said CEO Fred Lowery. "Our first-half performance and the sustained momentum have positioned us to raise our FY2026 guidance. Our value creation plans remain a top focus for our team, and we are on track to achieve our goals. As we sharpen our focus, our priorities ahead are accelerating growth, simplifying our business, driving operational rigor, and further deepening our customer relationships, all of which we believe will create sustainable shareholder value".
2026 EPS Consensus at $5.34, Revenue Growth View Raised to 4.5%-5.5%
2026 EPS consensus $5.34. Raises 2026 revenue growth view to 4.5%-5.5% from 3%-5%, consensus $13.75B. 2025 revenue was $13.18B.
Henry Schein Establishes Leadership Team, Restructures Executive Management
Henry Schein announced that it is creating the Henry Schein Leadership Team, HSLT, to replace its Executive Management Committee. The Company will also integrate its global supply chain organization with its global distribution group. The new leadership structure will continue to develop the Company's strategic priorities, accelerate its execution, and enhance enterprise collaboration. In addition, Michael Ettinger, the Company's Executive Vice President and Chief Operating Officer, Mark Mlotek, the Company's Executive Vice President and Chief Strategy Officer, and James Mullins, the Company's Senior Vice President, Global Supply Chain, will transition out of their roles effective October 30, 2026. Ettinger, Mlotek, and Mullins will continue in their roles until October 30th, and thereafter will remain as Senior Advisors to the Company.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.